Phase Ib PANTAX trial is successfully completed and establishes the maximal tolerated dose with positive safety profile and pharmacokinetic data.

Scandion Oncology (Scandion), a biotech company developing first-in-class medicines aimed at treating cancer which is resistant to current treatment options, announces the poster presentation of clinical safety and PK data from its PANTAX trial at the European Society for Medical Oncology (ESMO) Congress 2023 starting on October 20th in Madrid.

The poster presents data analysis from the PANTAX phase Ib trial, studying Scandion’s lead compound SCO-101 in combination with standard of care chemotherapies gemcitabine and nab-paclitaxel in patients with advanced pancreatic cancer. Topline results were announced in March 2023.

The data confirms that SCO-101 is safe and well-tolerated in this indication and combination, thereby also supporting the general profile of SCO-101 as well-tolerated in combination with different chemotherapies in patients with late-stage disease.

In the trial, dose limiting toxicity were observed in two patients in the cohort treated with 250 milligram of SCO-101, hence the maximum tolerated dose for SCO-101 concurrent with gemcitabine and nab-paclitaxel was determined to be 200 milligram once daily for 6 days on a bi-weekly schedule.

Data from the PK profile demonstrated that a 6-day schedule of SCO-101 resulted in SCO-101 accumulation and drug-exposure proportional to dose.

“We are excited to have the data from our successful dose finding in PANTAX communicated at the ESMO Congress, one of the most important events in the oncology community. We are very happy about the outcome of the trial and excited that it will now be shared with an audience of international experts”, says Lars Damstrup, MD, PhD, Chief Medical Officer at Scandion.

The poster abstract (titled “ABCG transporter and SRPK1 kinase inhibition of chemotherapy resistance: A phase Ib clinical trial of safety and maximum tolerated dose for SCO-101 in combination with gemcitabine and nab-paclitaxel in inoperable pancreatic cancer”) can be found at the congress website: https://www.esmo.org/meeting-calendar/esmo-congress-2023/abstracts

Scandion expects to present a final analysis of all safety and efficacy outcomes from PANTAX in the first half of 2024.

For further information please contact:
Johnny Stilou, CFO
Phone: +45 2960 3532
E-mail: [email protected]

The information was provided by the contact person above for publication on October 16, 2023, at 00.05 am CET.

Scandion Oncology (Scandion), the Cancer Drug Resistance Company, discovers and develops first-in-class medicines aimed at treating cancer which is resistant to current treatment options. We are at the forefront of this field, developing novel medicines that address cancer’s resistance against treatment. Our aim is to make existing cancer treatments work better and longer, thereby potentially prolonging and improving the life of patients who would otherwise have a high risk of dying from their cancer.

Globally, close to 10 million patients die every year from cancer and approximately 90 percent of all cancer related deaths are due to cancer drug resistance. Our medicines could be relevant in several different cancers. That makes both our medical and commercial potential significant.

Scandion is based in Copenhagen and its lead candidate, SCO-101, is currently being studied in clinical phase I and II trials. The company is listed on Nasdaq First North Growth Market Sweden (ticker: SCOL).

Västra Hamnen Corporate Finance is the Company's certified advisor on Nasdaq First North Growth Market.